Literature DB >> 16034453

HLA class II restricted T-cell receptor gene transfer generates CD4+ T cells with helper activity as well as cytotoxic capacity.

L T van der Veken1, M Hoogeboom, R A de Paus, R Willemze, J H F Falkenburg, M H M Heemskerk.   

Abstract

Both cytotoxic T cells and helper T cells are important in immune responses against pathogens and malignant cells. In hematological malignancies which express HLA class II molecules, immunotherapy may be directed to HLA class II restricted antigens. We investigated whether it is possible to engineer HLA class II restricted T cells with both antigen-specific cytolytic activity and the capacity to produce high amounts of cytokines. CD4+ and CD8+ peripheral-blood-derived T cells were retrovirally transduced with the HLA class II restricted minor histocompatibility antigen dead box RNA helicase Y (DBY)-specific TCR. The TCR-transduced CD4+ T cells exerted DBY-specific cytolytic activity, produced Th0, Th1, or Th2 cytokines, and proliferated upon DBY-specific stimulation. TCR-transduced CD8+ T cells exerted cytolytic activity which equaled the level of cytolytic activity of the TCR-transferred CD4+ T cells. Cotransfer of CD4 enhanced the cytolytic activity of the TCR-transduced CD8+ T cells, but introduction of CD4 was not sufficient to generate DBY-specific CD8+ T cells with the capacity to produce high amounts of cytokines. In this study, we demonstrated the feasibility to engineer T cells with antigen-specific cytolytic activity, as well as the ability to produce significant amounts of cytokines, by TCR transfer to CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034453     DOI: 10.1038/sj.gt.3302586

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

1.  Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies.

Authors:  Marleen M van Loenen; Renate de Boer; Renate S Hagedoorn; Esther H M van Egmond; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

Review 2.  Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.

Authors:  D L DiGiusto; L J N Cooper
Journal:  Cytotherapy       Date:  2007       Impact factor: 5.414

3.  A framework for highly multiplexed dextramer mapping and prediction of T cell receptor sequences to antigen specificity.

Authors:  Wen Zhang; Peter G Hawkins; Jing He; Namita T Gupta; Jinrui Liu; Gabrielle Choonoo; Se W Jeong; Calvin R Chen; Ankur Dhanik; Myles Dillon; Raquel Deering; Lynn E Macdonald; Gavin Thurston; Gurinder S Atwal
Journal:  Sci Adv       Date:  2021-05-14       Impact factor: 14.136

4.  Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity.

Authors:  Yi Zhang; Yeuying Liu; Kelly M Moxley; Lucy Golden-Mason; Michael G Hughes; Tongxin Liu; Mirjam H M Heemskerk; Hugo R Rosen; Michael I Nishimura
Journal:  PLoS Pathog       Date:  2010-07-29       Impact factor: 6.823

5.  Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer.

Authors:  Kirsten B J Scholten; Annelies W Turksma; Janneke J Ruizendaal; Muriel van den Hende; Sjoerd H van der Burg; Mirjam H M Heemskerk; Chris J L M Meijer; Erik Hooijberg
Journal:  J Transl Med       Date:  2011-09-05       Impact factor: 5.531

6.  TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.

Authors:  Trudy Straetemans; Mandy van Brakel; Sabine van Steenbergen; Marieke Broertjes; Joost Drexhage; Joost Hegmans; Bart N Lambrecht; Cor Lamers; Pierre van Der Bruggen; Pierre G Coulie; Reno Debets
Journal:  Clin Dev Immunol       Date:  2012-02-12

7.  Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.

Authors:  Lorenz Jahn; Dirk M van der Steen; Renate S Hagedoorn; Pleun Hombrink; Michel G D Kester; Marjolein P Schoonakker; Daniëlle de Ridder; Peter A van Veelen; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Oncotarget       Date:  2016-11-22

Review 8.  Targeting cancers through TCR-peptide/MHC interactions.

Authors:  Qinghua He; Xianhan Jiang; Xinke Zhou; Jinsheng Weng
Journal:  J Hematol Oncol       Date:  2019-12-18       Impact factor: 17.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.